Background To demonstrate the safety and efficacy of the intracameral use of tropicamide 0.02%/phenylephrine 0.31%/lidocaine 1% in pediatric cataract surgery, a combination widely used in adult patients but still off-label in children. Methods Design: two-center, prospective, observational study. Setting: San Giuseppe Hospital, Milan and Meyer Children's Hospital, Florence. Study population: children from 0 to 4 years of age undergoing cataract surgery with or without intraocular IOL implantation, in the absence of clinically significant systemic conditions, history of ocular surgery, concurrent ocular medication, hypersensitivity to any of the substances and post-traumatic cataracts. During the surgery, patients received the combination drug after the primary access to the anterior chamber. Efficacy was evaluated by achieving an adequate mydriasis in order to perform capsulorhexis, while safety was assessed by recording vital signs (heart rate, blood pressure, respiratory rate, temperature) pre- and post-administration of the substance. Results This study included 53 surgical procedures of 36 patients: 41 eyes were left aphakic, while 12 eyes received primary IOL implantation. The pupil size was adequate to safely perform capsulorhexis in 52 procedures of 53. The difference in pupil enlargement was significant (6.0 +/- 1.14 mm, P = < 0.001). There were no notable changes in vital parameters. Conclusions The administration of intracameral tropicamide 0.02%/phenylephrine 0.31%/lidocaine 1% in pediatric cataract surgery is effective for obtaining an adequate mydriasis without any vital parameters changes throughout the procedure.
Efficacy and safety of intraoperative use of tropicamide 0.02%/phenylephrine0.31%/lidocaine1% intracameral combination during pediatric cataract surgery / P. Nucci, A. Lembo, R. Caputo, A. Dellavalle, M. Serafino, I. Schiavetti, F. Pichi. - In: INTERNATIONAL OPHTHALMOLOGY. - ISSN 0165-5701. - 43:3(2023 Mar), pp. 989-995. [10.1007/s10792-022-02501-4]
Efficacy and safety of intraoperative use of tropicamide 0.02%/phenylephrine0.31%/lidocaine1% intracameral combination during pediatric cataract surgery
P. NucciPrimo
;
2023
Abstract
Background To demonstrate the safety and efficacy of the intracameral use of tropicamide 0.02%/phenylephrine 0.31%/lidocaine 1% in pediatric cataract surgery, a combination widely used in adult patients but still off-label in children. Methods Design: two-center, prospective, observational study. Setting: San Giuseppe Hospital, Milan and Meyer Children's Hospital, Florence. Study population: children from 0 to 4 years of age undergoing cataract surgery with or without intraocular IOL implantation, in the absence of clinically significant systemic conditions, history of ocular surgery, concurrent ocular medication, hypersensitivity to any of the substances and post-traumatic cataracts. During the surgery, patients received the combination drug after the primary access to the anterior chamber. Efficacy was evaluated by achieving an adequate mydriasis in order to perform capsulorhexis, while safety was assessed by recording vital signs (heart rate, blood pressure, respiratory rate, temperature) pre- and post-administration of the substance. Results This study included 53 surgical procedures of 36 patients: 41 eyes were left aphakic, while 12 eyes received primary IOL implantation. The pupil size was adequate to safely perform capsulorhexis in 52 procedures of 53. The difference in pupil enlargement was significant (6.0 +/- 1.14 mm, P = < 0.001). There were no notable changes in vital parameters. Conclusions The administration of intracameral tropicamide 0.02%/phenylephrine 0.31%/lidocaine 1% in pediatric cataract surgery is effective for obtaining an adequate mydriasis without any vital parameters changes throughout the procedure.File | Dimensione | Formato | |
---|---|---|---|
5d8a73a4-98ea-4469-982d-d98bf2b78d5b.pdf
accesso aperto
Descrizione: Research Article
Tipologia:
Pre-print (manoscritto inviato all'editore)
Dimensione
271.34 kB
Formato
Adobe PDF
|
271.34 kB | Adobe PDF | Visualizza/Apri |
s10792-022-02501-4-1.pdf
accesso riservato
Descrizione: Original Paper
Tipologia:
Publisher's version/PDF
Dimensione
533.55 kB
Formato
Adobe PDF
|
533.55 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.